EVRY, France--(BUSINESS WIRE)--IntegraGen, a biotechnology company dedicated to gene discovery and the development of molecular diagnostic products and services, announced today revenues for the year ending December 31, 2011. The company also announced the signing of two pharmacogenomic contracts and the launch of a new personalized sequencing service, the first offering of this type in France.
45% Growth of Sales for Genomic Services
The total revenue for IntegraGen’s Genomic Services was 4.6 M€ for 2011 representing a significant growth of +45% compared to 2010. With these results IntegraGen has confirmed its leadership on the French genomic and sequencing services market. The company’s significant revenue growth was a result of a very strong demand for high throughput sequencing reflecting expanding needs from academic and pharmaceutical research teams in terms of genome decrypting. During 2011, IntegraGen completed more than 130 projects for over one hundred different customers.
IntegraGen becomes the first services laboratory equipped with the new genomic sequencer MiSeq® System from Illumina
IntegraGen became the first European genomic services lab to be equipped with the MiSeq Sequencer from Illumina. Since this instrument allows targeted sequencing of parts of the genome in relatively short period of time, in as little as one day, its availability opens whole new fields of potential applications and opportunities to the Company. By making this technology available to its customers, IntegraGen continues to demonstrate leadership in the field of genomic services by providing expertise and access to advanced technology platforms.
Other key recent milestones include the signing of new contracts for pharmacogenomic research projects with two pharmaceutical companies and the Company’s participation in the 6th Meeting of the French Human and Medical Genetics in Marseilles, France where IntegraGen presented information on ERIS, company’s online software tool designed to simplify exome data analysis.
“We achieved an outstanding 2011 in terms of Genomic services sales. 2012 looks extremely promising as well,” stated Bernard Courtieu, IntegraGen’s Chief Executive Officer. “We have signed two very promising pharmacogenomic contracts, and as of today, we are the only Genomic Services laboratory to provide access to Illumina’s MiSeq in France. Although 2012 growth will likely be lower than in 2011, the Genomic Services activity will remain very strong and will contribute to the financing of our core Diagnostic activity in Autism and Oncology. In this regard, 2012 will be the year of major strategic advances for IntegraGen with the direct launch of the ARISk™ autism test in the USA, while important results related to our R&D activities in molecular diagnostics.”
Full year 2011 financial results will be published on the 23rd of April 2012, before market.
IntegraGen is a biotechnology company dedicated to gene discovery with the goal of developing molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen’s Genetic Services Business provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on autism and oncology, IntegraGen’s core strategy is to deliver a portfolio of high value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.
As of Dec, 31st, 2011 IntegraGen employed 26 employees. The Company published revenues for 2011 of 4.6 M€. The company’s headquarters is in Evry, France with a U.S. subsidiary, IntegraGen, Inc., based in Cambridge, Massachusetts.
IntegraGen is listed on the Alternext market of the NYSE Euronext in Paris (Isin: FR0010908723 - Mnémo: ALINT)
More information on www.integragen.com